TABLE 2

Overview of baseline demographics and disease characteristics: treated set

NinoTinA-asthma [23]CanoTinA-asthma [21]VivaTinA-asthma [20]RubaTinA-asthma [17]PensieTinA-asthma [18]
Subjects101401400397392
Male61 (60.4)264 (65.8)279 (69.8)258 (65.0)242 (61.7)
Age years3.0 (1–5)9.0 (6–11)9.0 (6–11)14.0 (11–17)14.0 (12–17)
Race
 White77 (76.2)339 (84.5)358 (89.5)368 (92.7)371 (94.6)
 Asian17 (16.8)10 (2.5)2 (0.5)13 (3.3)10 (2.6)
 Black/African-American7 (6.9)7 (1.7)5 (1.3)14 (3.5)8 (2.0)
 American Indian/Alaska  Native045 (11.2)35 (8.8)2 (0.5)3 (0.8)
 Hawaiian/Pacific Islander00000
Ethnicity
 Hispanic/Latino055 (13.7)72 (18.0)42 (10.6)68 (17.3)
Never-smoker396 (99.7)392 (100)
No exposure to second-hand smoke92 (91.1)372 (92.8)369 (92.3)353 (88.9)367 (93.6)
Age at onset of asthma years1.5±1.24.7±2.44.1±2.46.5±4.16.5±3.9
Duration of asthma years1.3 (0.5–5.0)4.0 (0.5–11.0)4.8 (0.6–11.0)8.0 (0.3–16.3)8.0 (0.3–16.5)
Concomitant diagnoses
 Allergic rhinitis20 (19.8)230 (57.4)238 (59.5)219 (55.2)225 (57.4)
 Atopic dermatitis17 (16.8)55 (13.7)38 (9.5)37 (9.3)38 (9.7)
FEV1 % pred84.06±10.7981.64±11.4582.79±10.5679.52±11.49
FEV1 % reversibility26.48±12.4127.43±13.4326.80±12.8629.19±14.26
ACQ score#1.868±0.311.966±0.362.03±0.432.13±0.43
Concomitant therapies at baseline
 LTRAs41 (40.6)107 (26.7)339 (84.8)33 (8.3)315 (80.4)
 LABAs8 (7.9)1 (0.2)313 (78.3)1 (0.3)324 (82.7)
ICS dose of stable maintenance treatment μg·day−1 budesonide or equivalent255.2±187.4310.0±112.0457.4±236.0539.4±292.7747.0±357.7

Data are presented as n, n (%), median (range) or mean±sd. FEV1: forced expiratory volume in 1 s; % pred: % predicted; ACQ: Asthma Control Questionnaire; LTRA: leukotriene receptor antagonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid. #: interviewer-administered ACQ in CanoTinA-asthma and VivaTinA-asthma.